Injecting microscopic fibers that remove plaque deposits from artery walls reversed atherosclerosis in preliminary research.
Embargoed for 2 PM Pacific Time/5 PM Eastern Time, Friday May 11, 2018
SAN FRANCISCO – An injection may one day be able to reverse atherosclerosis, according to emerging research presented at the American Heart Association’s Vascular Discovery: From Genes to Medicine Scientific Sessions 2018, a premier global exchange of the latest advances in vascular biology for researchers and clinicians.
Atherosclerosis is characterized by a narrowing of arteries and blood vessels caused by a build-up of a hard, waxy substance called plaque, which is rich in cholesterol.
Drugs such as statins are used to control low density lipoprotein (LDL) the so-called bad cholesterol and thus decrease “plaque burden”, explained Neel A. Mansukhani, M.D. lead author of the study and an integrated vascular surgery fellow at Northwestern University Feinberg School of Medicine in Chicago. “But statins have not been proven to reverse the disease.” Mansukhani said.
Other treatment approaches for atherosclerosis, which can narrow blood vessels and arteries throughout the body, include bypass surgery and stenting, but neither reverses the disease and each can cause damage to the vessel wall, he said.
“Our aim was to develop a non-invasive, non-surgical, novel therapy to halt and reverse the disease by actually targeting the vessel wall with peptide-based nanofibers developed in the laboratory,” Mansukhani said. The tiny fibers contained particles that helped remove cholesterol deposits from the plaque in the artery walls.
Researchers synthesized self-assembling peptide amphile nanofibers that targeted areas of plaque and could be delivered by intravenous injection. Importantly these synthetically engineered nanofibers contained an amino acid sequence that promotes the cholesterol to dissolve.
To test the concept, mice were genetically modified to rapidly develop atherosclerosis, then fed high fat diets for 14 weeks and after which the mice received biweekly injections of either the peptide amphile nanofiber or saline for 8 weeks.
“It was important that we were able to achieve reproducible results in this model in the lab, so first we wanted to confirm that the therapy actually targeted areas of atherosclerosis,” Mansukhani said.
They used imaging techniques -- fluorescent microscopy and pixel quantification -- to determine optimum dose, concentration, binding duration and biodistribution and found they could observe the targeting effect after 24 hours, and after 48 to 72 hours the nanofiber would dissipate and it was cleared in 7 to 10 days.
After 8 weeks of treatment, plaque area in the arteries of the male mice was reduced by 11 percent and in the female mice by 9 percent.
The results “demonstrate that a novel targeted nanofiber binds specifically to atherosclerotic lesions and reduces plaque burden after a short treatment duration,” Mansukhani said.
He noted, however, that this is preliminary research, and more is needed before this approach can be tested in humans.
Co-authors are Miranda So, M.S.; Mazen; S. Albgaghdadi, M.D.; Zheng Wang, B.A.; Samuel I. Stupp, Ph.D.; Erica B. Peters, Ph.D. and Melina R. Kibbe, M.D.
The study was funded by the National Institutes of Health/National Heart Lung and Blood Institute; Northwestern Memorial Foundation Dixon Translational Sciences Award.
- For more news about the American Heart Association’s Vascular Discovery: From Genes to Medicine Scientific Sessions 2018, follow us on Twitter @HeartNews #ATVB18
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.
For Media Inquiries and AHA/ASA Spokesperson Perspective: 214-706-1173
Darcy Spitz : 212-878-5940; email@example.com
For Public Inquiries: 1-800-AHA-USA1 (242-8721)